Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Biotechnology

Healthcare
$4.26 +2.67%

+$0.19 today

Market cap
$71.70M
Beta
1.52
P/E (TTM)
0.0
EPS (TTM)
$407.81
52W Low $6.42High $31.50

Volume 0.06M

Average 0.44M

ENLV Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Enlivex Therapeutics Ltd.NASDAQ: ENLV

Weighted Avg Shares · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares growth accelerates

Q4 FY2025 weighted avg shares of 3.03M shares rose 107.6% year over year, ahead of the +41.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 89.0% from the prior quarter. Over 3 fiscal years it compounded at +35.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +107.6% holds above the trailing-twelve-month pace of +41.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
3.03M+89.0% QoQ
Last fiscal yearDec 2025
3.05M+122.8% YoY
LTMDec 2025
1.92M+41.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+107.6%——
1 year+122.8%——
3-year CAGR+35.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
3.05M USD
Year-over-year change
+122.8%
4-year CAGR
+26.5%

Weighted Avg Shares vs competitors

How ENLV compares with its peers on the latest reported figures

  • ENLV's LTM Dec 2025 weighted avg shares of 1.92M shares is the lowest of the 2 companies compared; the peer median is 9.61M shares.
  • Its year-over-year change of +41.5% is the highest of 2, against a peer median of +35.9%.
  • Over three fiscal years its annual growth of +35.4% compares with a peer median of +2.6%.
ENLV Competitors Peer median
Weighted Avg Shares for ENLV and competitors
Company Period LTM YoY 3-year CAGR
NRXSNeurAxis, Inc.LTM Mar 20269.61M +35.9%+2.6%
ENLVEnlivex Therapeutics Ltd.LTM Dec 20251.92M +41.5%+35.4%
Peer median (excluding ENLV) 9.61M+35.9%+2.6%

Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue546K777K835K545K332K
Gross Profit(546K)(777K)(835K)(545K)(332K)
Gross Margin—————
Research & Development12.88M18.69M19.24M10.13M8.92M
Selling, General & Admin6.24M6.7M6.14M4.91M5.69M
Operating Expenses19.29M25.8M29.4M14.99M14.67M
Depreciation & Amortization546K777K835K545K332K
EBITDA(18.74M)(25.02M)(28.22M)(14.47M)(14.67M)
EBITDA Margin—————
Operating Income(19.29M)(25.8M)(29.4M)(15.54M)(15M)
Operating Margin—————
Interest Income120K835K1.57M1.07M792K
Interest Expense328K5.26M14K13K13K
Other Income / Expenses4.82M(5.26M)327K522K1.63B
Income Before Tax(14.47M)(31.06M)(29.07M)(15.01M)1.62B
Pre-Tax Margin—————
Income Tax Expense0000382.65M
Net Income(14.47M)(31.06M)(29.07M)(15.01M)1.24B
Net Margin—————
EPS (Basic)(8.10)(34.65)(23.40)(10.95)405.60
EPS (Diluted)(8.10)(34.65)(23.40)(10.95)382.20
Weighted Avg Shares1.19M1.23M1.24M1.37M3.05M
Weighted Avg Shares (Diluted)1.19M1.23M1.24M1.37M3.23M

Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Intrinsic Alpha fair value

Locked

Current Price

$4.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.